Last €2.08 EUR
Change Today -0.009 / -0.43%
Volume 1.0K
NB1 On Other Exchanges
As of 3:19 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

biota pharmaceuticals inc (NB1) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/5/14 - €5.06
52 Week Low
09/24/14 - €1.61
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

biota pharmaceuticals inc (NB1) Related Businessweek News

No Related Businessweek News Found

biota pharmaceuticals inc (NB1) Details

Biota Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing oral, small molecule compounds to treat various respiratory-related viral infections. Its advanced clinical-stage program is laninamivir octanoate, a long-acting neuraminidase inhibitor for the treatment of influenza A and B. The company also develops vapendavir, which completed Phase II trials for the treatment of human rhinovirus infections in patients with moderate to severe asthma, as well as completed additional Phase 1 bioavailability and drug-drug interaction studies. In addition, it develops orally bioavailable F and non-F protein compounds for the treatment of respiratory syncytial virus infections in children, the elderly, and immune-compromised patients. Biota Pharmaceuticals, Inc. is headquartered in Alpharetta, Georgia.

66 Employees
Last Reported Date: 09/30/14

biota pharmaceuticals inc (NB1) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: $408.0K
Executive Chairman
Total Annual Compensation: $525.0K
Compensation as of Fiscal Year 2014.

biota pharmaceuticals inc (NB1) Key Developments

Biota Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended September 30, 2014

Biota Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the first quarter ended September 30, 2014. For the period, the company reported total revenue was $0.7 million compared to $12.3 million a year ago, due to an $11.6 million decrease in contract service revenue related to the cancellation of the company's contract with the Biomedical Advanced Research and Development Authority (BARDA) on May 7, 2014 for the convenience of the U.S. Government. Loss from operations was $7.0 million compared to $4.1 million a year ago. Loss before tax was $6.9 million compared to $4.0 million a year ago. Net loss was $6.9 million or $0.20 basic and diluted per share compared to $3.9 million or $0.14 basic and diluted per share a year ago. The $3.0 million increase in net loss in 2014 was primarily due to a $11.6 million decrease in revenue, a $1.9 million increase in research and development expense and $0.1 million reduction in income tax benefit, offset in part by a $9.0 million decrease in the cost of revenue and a $1.6 million change from a foreign exchange loss in 2013 to a gain in 2014. Research and development expense increased to $4.9 million for the three month period ended September 30, 2014 from $3.0 million in the same period of 2013.

Biota Pharmaceuticals, Inc. to Report Q1, 2015 Results on Nov 07, 2014

Biota Pharmaceuticals, Inc. announced that they will report Q1, 2015 results at 9:00 AM, US Eastern Standard Time on Nov 07, 2014

Biota Pharmaceuticals, Inc., Q1 2015 Earnings Call, Nov 07, 2014

Biota Pharmaceuticals, Inc., Q1 2015 Earnings Call, Nov 07, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NB1:GR €2.08 EUR -0.009

NB1 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Roche Holding AG SFr.248.60 CHF -4.10
View Industry Companies

Industry Analysis


Industry Average

Valuation NB1 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.5x
Price/Book 1.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOTA PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at